BDRX (Biodexa Pharmaceuticals) Marketable Securities: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.10
GF Value $1.82
View Full Analysis

What is Biodexa Pharmaceuticals Marketable Securities?

Biodexa Pharmaceuticals BDRX 45 Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $1.82.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Biodexa Pharmaceuticals's Marketable Securities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Biodexa Pharmaceuticals  (NAS:BDRX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Biodexa Pharmaceuticals Marketable Securities Related Terms

Biodexa Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals Marketable Securities Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Biodexa Pharmaceuticals (BDRX) has a Marketable Securities of $0.00 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biodexa Pharmaceuticals and its competitors.
Is Biodexa Pharmaceuticals' Marketable Securities too high?
Biodexa Pharmaceuticals' current Marketable Securities is $0.00 Mil. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' Marketable Securities compare to ADTX and AAGH?
Biodexa Pharmaceuticals' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Biodexa Pharmaceuticals (BDRX) has a current Marketable Securities of $0.00 Mil. The stock's GF Value™ is $1.82, compared to a current price of $2.10 — trading 15.4% above its estimated fair value. The current Marketable Securities is $0.00 Mil. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current Marketable Securities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.10 is trading 15.4% above its estimated GF Value™ of $1.82.

Key valuation signals for BDRX:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $1.82 vs. price of $2.10 (15.4% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$1.82
GF Value